Krajewska J, Zub K, Slowikowski A, Zatonski T (2022) Chronic rhinosinusitis in cystic fibrosis: a review of therapeutic options. Eur Arch Otorhinolaryngol 279(1):1–24. https://doi.org/10.1007/s00405-021-06875-6

Article  Google Scholar 

Loebinger MR, Bilton D, Wilson R (2009) Upper airway 2: bronchiectasis, cystic fibrosis and sinusitis. Thorax 64(12):1096–1101. https://doi.org/10.1136/thx.2008.112870

Article  CAS  Google Scholar 

Gentile VG, Isaacson G (1996) Patterns of sinusitis in cystic fibrosis. Laryngoscope 106(8):1005–1009. https://doi.org/10.1097/00005537-199608000-00018

Article  CAS  Google Scholar 

Leong S, Sharma RK, Safi C, DiMango E, Keating C, Gudis DA, Overdevest JB (2021) Association of quality of life measures and otolaryngologic care in cystic fibrosis patients. Ann Otol Rhinol Laryngol. https://doi.org/10.1177/00034894211045636

Article  Google Scholar 

Gysin C, Alothman GA, Papsin BC (2000) Sinonasal disease in cystic fibrosis: clinical characteristics, diagnosis, and management. Pediatr Pulmonol 30(6):481–489. https://doi.org/10.1002/1099-0496(200012)30:6%3c481::aid-ppul8%3e3.0.co;2-n

Article  CAS  Google Scholar 

Bonestroo HJ, de Winter-de Groot KM, van der Ent CK, Arets HG (2010) Upper and lower airway cultures in children with cystic fibrosis: do not neglect the upper airways. J Cyst Fibros 9(2):130–134. https://doi.org/10.1016/j.jcf.2010.01.001

Article  Google Scholar 

Karanth TK, Karanth V, Ward BK, Woodworth BA, Karanth L (2022) Medical interventions for chronic rhinosinusitis in cystic fibrosis. Cochrane Database Syst Rev 4:CD012979. https://doi.org/10.1002/14651858.CD012979.pub3

Article  Google Scholar 

Spielman DB, Beswick DM, Kimple AJ, Senior BA, Aanaes K, Woodworth BA, Schlosser RJ, Lee S, Cho DY, Adappa ND et al (2021) The management of cystic fibrosis chronic rhinosinusitis: an evidenced-based review with recommendations. Int Forum Allergy Rhinol. https://doi.org/10.1002/alr.22953

Article  Google Scholar 

Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM et al (2019) Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394(10212):1940–1948. https://doi.org/10.1016/S0140-6736(19)32597-8

Article  CAS  Google Scholar 

Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F et al (2019) Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 381(19):1809–1819. https://doi.org/10.1056/NEJMoa1908639

Article  CAS  Google Scholar 

Hayes D Jr, McCoy KS, Sheikh SI (2014) Improvement of sinus disease in cystic fibrosis with ivacaftor therapy. Am J Respir Crit Care Med 190(4):468. https://doi.org/10.1164/rccm.201403-0595IM

Article  Google Scholar 

Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D Jr (2015) Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation. Clin Otolaryngol 40(1):16–21. https://doi.org/10.1111/coa.12310

Article  CAS  Google Scholar 

Vreede CL, Berkhout MC, Sprij AJ, Fokkens WJ, Heijerman HG (2015) Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N. J Cyst Fibros 14(3):412–413. https://doi.org/10.1016/j.jcf.2014.07.013

Article  CAS  Google Scholar 

McCormick J, Cho DY, Lampkin B, Richman J, Hathorne H, Rowe SM, Woodworth BA (2019) Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients. Int Forum Allergy Rhinol 9(3):292–297. https://doi.org/10.1002/alr.22251

Article  Google Scholar 

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA et al (2015) Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373(3):220–231. https://doi.org/10.1056/NEJMoa1409547

Article  CAS  Google Scholar 

Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E et al (2018) VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med 379(17):1612–1620. https://doi.org/10.1056/NEJMoa1807120

Article  CAS  Google Scholar 

Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, Drescher M, Minso R, Ringshausen FC, Rueckes-Nilges C et al (2022) Effects of elexacaftor/tezacaftor/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles. Am J Respir Crit Care Med 205(5):540–549. https://doi.org/10.1164/rccm.202110-2249OC

Article  CAS  Google Scholar 

DiMango E, Overdevest J, Keating C, Francis SF, Dansky D, Gudis D (2021) Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis. J Cyst Fibros 20(3):460–463. https://doi.org/10.1016/j.jcf.2020.07.002

Article  CAS  Google Scholar 

Douglas JE, Civantos AM, Locke TB, Sweis AM, Hadjiliadis D, Hong G, Dorgan DJ, Kohanski MA, Palmer JN, Adappa ND (2021) Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis. Int Forum Allergy Rhinol 11(2):201–203. https://doi.org/10.1002/alr.22716

Article  Google Scholar 

Shakir S, Echevarria C, Doe S, Brodlie M, Ward C, Bourke SJ (2022) Elexacaftor-tezacaftor-ivacaftor improve gastro-oesophageal reflux and sinonasal symptoms in advanced cystic fibrosis. J Cyst Fibros. https://doi.org/10.1016/j.jcf.2022.06.003

Article  Google Scholar 

Beswick DM, Humphries SM, Balkissoon CD, Strand M, Vladar EK, Lynch DA, Taylor-Cousar JL (2022) Impact of cystic fibrosis transmembrane conductance regulator therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient-reported outcomes. Ann Am Thorac Soc 19(1):12–19. https://doi.org/10.1513/AnnalsATS.202101-057OC

Article  Google Scholar 

Wucherpfennig L, Triphan SMF, Wege S, Kauczor HU, Heussel CP, Schmitt N, Wuennemann F, Mayer VL, Sommerburg O, Mall MA et al (2022) Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis. J Cyst Fibros. https://doi.org/10.1016/j.jcf.2022.03.011

Article  Google Scholar 

Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP (2009) Psychometric validity of the 22-item sinonasal outcome test. Clin Otolaryngol 34(5):447–454. https://doi.org/10.1111/j.1749-4486.2009.01995.x

Article  CAS  Google Scholar 

Riedl D, Dejaco D, Steinbichler TB, Innerhofer V, Gottfried T, Bektic-Tadic L, Giotakis AI, Rumpold G, Riechelmann H (2021) Assessment of health-related quality-of-life in patients with chronic Rhinosinusitis - Validation of the German Sino-Nasal Outcome Test-22 (German-SNOT-22). J Psychosom Res. 140:110316. https://doi.org/10.1016/j.jpsychores.2020.110316

Article  CAS  Google Scholar 

Dejaco D, Riedl D, Huber A, Moschen R, Giotakis AI, Bektic-Tadic L, Steinbichler T, Kahler P, Riechelmann H (2019) The SNOT-22 factorial structure in European patients with chronic rhinosinusitis: new clinical insights. Eur Arch Otorhinolaryngol 276(5):1355–1365. https://doi.org/10.1007/s00405-019-05320-z

Article  CAS  Google Scholar 

Beswick DM, Humphries SM, Balkissoon CD, Strand M, Vladar EK, Ramakrishnan VR, Taylor-Cousar JL (2022) Olfactory dysfunction in cystic fibrosis: impact of CFTR modulator therapy. J Cyst Fibros 21(2):e141–e147. https://doi.org/10.1016/j.jcf.2021.09.014

Article  Google Scholar 

Kimple AJ, Senior BA, Naureckas ET, Gudis DA, Meyer T, Hempstead SE, Resnick HE, Albon D, Barfield W, Benoit MM et al (2022) Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations. Int Forum Allergy Rhinol. https://doi.org/10.1002/alr.22974

Article  Google Scholar